How Gilead finally spent its money

This year, under a new leadership team, the company inked more than half a dozen deals that provide access to a slate of experimental cancer drugs and a marketed therapy for breast tumors. At a combined value of over $27 billion, the deals are Gilead's most substantial push yet to transform into a leader in cancer treatment.